42.28
+1.0293(+2.50%)
Currency In USD
| Previous Close | 41.25 |
| Open | 39 |
| Day High | 42.34 |
| Day Low | 39 |
| 52-Week High | 57.99 |
| 52-Week Low | 25.83 |
| Volume | 40,381.32 |
| Average Volume | 1.12M |
| Market Cap | 4.43B |
| PE | -8.54 |
| EPS | -4.95 |
| Moving Average 50 Days | 38.51 |
| Moving Average 200 Days | 40.72 |
| Change | 1.03 |
Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences in March
GlobeNewswire Inc.
Feb 05, 2026 9:05 PM GMT
SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that company management will participate in the following two upcoming investor conferences: TD Cowen 46th Annual Health Care Conference, B
Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
GlobeNewswire Inc.
Jan 26, 2026 10:00 PM GMT
SAN DIEGO, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026 after the market closes. Company mana
Crinetics Initiates Phase 2/3 Pediatric Trial Evaluating Atumelnant in Congenital Adrenal Hyperplasia (CAH)
GlobeNewswire Inc.
Jan 22, 2026 9:05 PM GMT
First in class study of an investigational ACTH receptor antagonist aims to address significant unmet need in children and adolescents with classic CAHSAN DIEGO, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today